0001870404
Company
CERO THERAPEUTICS HOLDINGS, INC.
Biological Products, (No Diagnostic Substances) · CERO
follow-on
priced
OTCQB
424B3
Filing Timeline
SEC EDGAR
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
729,596,950 shares
Common · Exchange OTCQB · Ticker CERO · Public warrants traded under CEROW
2026-03-11 · 0001213900-26-025853
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
729,596,950 shares
common · Exchange OTCQB · Ticker CERO
2026-02-20 · 0001213900-26-018804
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
729,596,950 shares
Common Stock · Exchange OTCQB · Ticker CERO · Warrants exercisable for one two-thousandths of a share of Common Stock
2026-02-04 · 0001213900-26-011847
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
729,596,950 shares
Common Stock · Exchange OTCQB · Ticker CERO · Underwriters self-underwritten
2026-02-03 · 0001213900-26-011601
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
729,596,950 shares
Common Stock · Exchange OTCQB · Ticker CERO · Public warrants exercisable for one two-thousandths of a share of common stock · Flags warrants
2026-01-08 · 0001213900-26-002515
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
729,596,950 shares
Common Stock · Exchange OTCQB · Ticker CERO · Public warrants exercisable for one two-thousandths of a share of common stock
2025-12-19 · 0001213900-25-123953
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1 and marks the registration effective.
2025-12-11 · 9999999995-25-003686
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 424B3 in the pre-IPO sequence.
729,596,950 shares
Common Stock · Exchange OTCQB · Ticker CERO · Selling stockholders only · Use of proceeds No issuer proceeds; proceeds go to selling stockholders · Underwriters Keystone Capital Partners, LLC
2025-12-05 · 0001213900-25-118817
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
12,500,000 shares
Common Stock · Exchange OTC · Ticker CERO · Public warrants (CEROW) exercisable for one two-thousandths of a share of common stock
2025-12-02 · 0001213900-25-117352
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
Common Stock · Exchange OTC · Ticker CERO
2025-12-02 · 0001213900-25-117357
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
12,500,000 shares
Common Stock · Exchange OTC Pink Sheets · Ticker CERO · Public warrants exercisable for one two-thousandths of a share of common stock
2025-11-20 · 0001213900-25-113117
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
Common Stock · Exchange OTC · Ticker CERO · Public warrants exercisable for one two-thousandths of a share of Common Stock (CEROW)
2025-11-20 · 0001213900-25-113118
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
12,500,000 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker CERO · Use of proceeds funding operations and clinical trials
2025-10-30 · 0001213900-25-104117
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
Common Stock · Exchange Nasdaq · Ticker CERO · Public warrants (CEROW) exercisable for one two-thousandths of a share of common stock
2025-10-30 · 0001213900-25-104118
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
12,500,000 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker CERO
2025-10-23 · 0001213900-25-101650
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker CERO · Public warrants exercisable for one two-thousandth of a share of Common Stock (CEROW)
2025-10-23 · 0001213900-25-101651
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
12,500,000 shares
Common Stock · Exchange Nasdaq · Ticker CERO
2025-09-05 · 0001213900-25-085121
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker CERO · Public warrants exercisable for one two-thousandth of a share of Common Stock
2025-09-05 · 0001213900-25-085127
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
12,500,000 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker CERO · Each whole warrant exercisable for one two-thousandths of a share of common stock · Flags warrants
2025-09-04 · 0001213900-25-084604
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
2,100,000 Shares of Common Stock · Exchange NASDAQ · Ticker CERO · Use of proceeds general corporate purposes · Flags self_underwritten · Underwriters self-underwritten
2025-09-04 · 0001213900-25-084610
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2,100,000 shares
Shares of Common Stock · Exchange Nasdaq Capital Market · Ticker CERO
2025-08-22 · 0001213900-25-080011
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
12,500,000 shares
Common Stock · Exchange Nasdaq · Ticker CERO · Use of proceeds working capital, clinical development, and general corporate purposes
2025-08-22 · 0001213900-25-080017
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2025-08-15 · 9999999995-25-002650
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2025-07-29 · 9999999995-25-002395
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
2,100,000 shares
Common Stock · Exchange Nasdaq · Ticker CERO
2025-07-25 · 0001213900-25-067733
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 424B3 in the pre-IPO sequence.
12,500,000 shares · Gross proceeds $25,000,000
Common Stock · Exchange Nasdaq Capital Market · Ticker CERO · Selling stockholders only · Use of proceeds Proceeds from the sale will go to Keystone, as the company is not receiving any proceeds · Underwriters Keystone Capital Partners, LLC
2025-07-21 · 0001213900-25-066152
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-07-14 · 0001213900-25-063764
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
Common · Exchange Nasdaq Capital Market · Ticker CERO · Public warrants exercisable for one two-thousandth of a share of Common Stock (CEROW)
2025-07-02 · 0001213900-25-061023
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker CERO
2025-06-25 · 0001213900-25-057780
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2,100,000 shares
Common Stock · Exchange NASDAQ · Ticker CERO
2025-06-16 · 0001213900-25-054769
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2,100,000 shares
Shares of Common Stock · Exchange NASDAQ · Ticker CERO · Public warrants (CEROW) listed on Nasdaq
2025-06-06 · 0001213900-25-052185
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2025-05-29 · 9999999995-25-001765
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
Price $1.96 · 2,551,020 shares · Gross proceeds $5,000,000
Common Stock, par value $0.0001 per share · Exchange NASDAQ · Ticker CERO · Warrants exercisable at $1.96 per share for 5 years, immediately exercisable upon shareholder approval · Use of proceeds Advancement of clinical programs and working capital · Flags warrants · Underwriters A.G.P./Alliance Global Partners
2025-02-13 · 0001213900-25-013492
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-02-13 · 0001213900-25-013493
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-02-13 · 0001213900-25-013494
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
Price $1.96 · 2,551,020 shares · Gross proceeds $5,000,000
Common Stock · Exchange NASDAQ Global Market · Ticker CERO · Warrants exercisable for one share at $1.96, 5-year term · Use of proceeds for advancement of its clinical programs and working capital · Flags best_efforts, warrants · Underwriters A.G.P./Alliance Global Partners
2025-02-13 · 0001213900-25-013495
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $1.96 · 300,000 shares · Gross proceeds $5,000,000
Shares of Common Stock · Exchange NASDAQ · Ticker CERO · Offered Common Warrants with exercise price $1.96, exercisable immediately upon stockholder approval, expiring 5 years after approval · Use of proceeds Proceeds will be used for general corporate purposes · Flags warrants · Underwriters A.G.P./Alliance Global Partners
2025-02-07 · 0001213900-25-011071
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior 424B3 filing.
2025-02-05 · 0001213900-25-010230
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
2025-02-05 · 9999999995-25-000319
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1/A and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange Nasdaq Global Market · Ticker CERO · Public warrants exercisable for one share of common stock at $0.0154 per warrant · Use of proceeds To increase stockholders' equity through capital raising activities · Flags warrants
2025-01-23 · 0001213900-25-005621
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common · Exchange Nasdaq Global Market · Ticker CERO · Use of proceeds Proceeds will be used for capital raising to attain stockholders' equity
2025-01-23 · 0001213900-25-005623
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
638,563,750 shares
Common Stock · Exchange Nasdaq Global Market · Ticker CERO · Warrants exercisable for one share of common stock · Use of proceeds capital raising to increase stockholders' equity
2025-01-23 · 0001213900-25-005624
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-01-23 · 0001213900-25-005625
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior 424B3 filing.
4,000,000 shares
Common Stock · Exchange Nasdaq · Ticker CERO · Shares and warrants · Offered Common Warrants with exercise price $2.34 and Pre-Funded Warrants with exercise price $0.001 · Flags units, warrants
2025-01-21 · 0001213900-25-004742
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-01-14 · 0001213900-25-003433
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-01-14 · 0001213900-25-003434
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common Stock · Exchange NASDAQ · Ticker CERO · Warrants exercisable for one share of common stock · Use of proceeds Working capital and general corporate purposes
2025-01-14 · 0001213900-25-003435
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange Nasdaq Global Market · Ticker CERO · Warrants to purchase 16,385,275 shares of Common Stock at $0.0582 per share
2025-01-14 · 0001213900-25-003436
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common Stock · Exchange NASDAQ Global Market · Ticker CERO · Public warrants (CEROW) exercisable for one share of common stock · Use of proceeds Proceeds not specified in filing
2025-01-07 · 0001213900-25-001657
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
638,563,750 shares
Common Stock · Exchange Nasdaq Global Market · Ticker CERO · Warrants to purchase common stock at $0.0561 per share
2025-01-07 · 0001213900-25-001658
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
210,000,000 shares
Common Stock · Exchange NASDAQ · Ticker CERO · Public warrants exercisable for one share of common stock · Flags warrants
2025-01-07 · 0001213900-25-001660
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-01-07 · 0001213900-25-001661
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange Nasdaq Global Market · Ticker CERO · 8,405,942 warrants to purchase common stock at $0.0561 per share issued on Dec 23, 2024 · Use of proceeds To facilitate preferred stock conversions and warrant exercises
2025-01-03 · 0001213900-25-000474
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common Stock · Exchange NASDAQ · Ticker CERO · Warrants to purchase 8,405,942 shares of Common Stock issued on Dec 23, 2024 at $0.0561 exercise price
2025-01-03 · 0001213900-25-000475
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
210,000,000 shares
Common Stock · Exchange Nasdaq Global Market · Ticker CERO · Warrants to purchase 8,405,942 shares of Common Stock at $0.0561 per share · Use of proceeds Working capital and general corporate purposes
2025-01-03 · 0001213900-25-000477
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows EFFECT in the pre-IPO sequence.
Common Stock · Exchange Nasdaq · Ticker CERO · Pre-Funded Warrants and Common Warrants to purchase shares of Common Stock · Use of proceeds Working capital
2024-12-23 · 0001213900-24-111475
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
2024-12-05 · 0001213900-24-106094
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2024-12-05 · 0001213900-24-106096
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2024-12-05 · 9999999995-24-003674
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2024-12-05 · 9999999995-24-003681
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows S-1/A in the pre-IPO sequence.
210,000,000 shares
Common Stock · Exchange Nasdaq · Ticker CERO · Selling stockholders only · Use of proceeds Selling stockholders are offering shares; no proceeds to the company · Underwriters Keystone Capital Partners, LLC
2024-11-27 · 0001213900-24-103009
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior 424B3 filing.
638,563,750 shares · Gross proceeds $0.00
Common Stock · Series C Warrants exercisable at $0.098 per share and Preferred Warrants exercisable at $800 per share · Selling stockholders only · Use of proceeds No proceeds to the company from the resale; proceeds from warrant exercises not anticipated
2024-11-25 · 0001213900-24-101756
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2024-11-20 · 0001213900-24-100585
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2024-11-20 · 0001213900-24-100589
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange Nasdaq · Ticker CERO
2024-11-19 · 0001213900-24-099804
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common Stock · Exchange Nasdaq · Ticker CERO
2024-11-19 · 0001213900-24-099806
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common Stock · Exchange NASDAQ · Ticker CERO · Public warrants listed on Nasdaq under CEROW · Use of proceeds 25% of net proceeds to redeem Series C Convertible Preferred Stock · Flags warrants
2024-11-12 · 0001213900-24-096248
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2024-11-12 · 0001213900-24-096250
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1/A and confirms the priced prospectus.
2024-11-01 · 0001213900-24-093576
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange NASDAQ · Ticker CERO · Public warrants exercisable for one share of common stock each
2024-11-01 · 0001213900-24-093579
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior 424B3 filing.
2024-10-22 · 0001213900-24-089411
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 424B3 in the pre-IPO sequence.
713,563,749 shares
Common Stock · Warrants to purchase common stock at exercise prices ranging from $0.0196 to $1.39 · Selling stockholders only · Use of proceeds No proceeds to the issuer; resale by selling stockholders · Underwriters self-underwritten
2024-10-21 · 0001213900-24-089326
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange NASDAQ · Ticker CERO
2024-10-21 · 0001213900-24-089110
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common Stock · Exchange Nasdaq · Ticker CERO
2024-10-21 · 0001213900-24-089111
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange Nasdaq Global Market · Ticker CERO · Public warrants exercisable for one share of common stock (CEROW) · Use of proceeds Working capital
2024-10-11 · 0001213900-24-087298
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common · Exchange NASDAQ · Ticker CERO · Warrants exercisable for one share of common stock
2024-10-11 · 0001213900-24-087305
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange NASDAQ · Ticker CERO · Warrants to purchase 8,175,166 shares of common stock · Flags warrants
2024-10-04 · 0001213900-24-085649
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2024-10-04 · 0001213900-24-085650
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2024-09-26 · 0001213900-24-081975
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange NASDAQ · Ticker CERO · Warrants to purchase 8,175,166 shares of common stock
2024-09-26 · 0001213900-24-081979
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
26,619,050 shares
Common Stock · Exchange NASDAQ · Ticker CERO
2024-08-02 · 0001213900-24-064720
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2024-08-02 · 0001213900-24-064721
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2024-07-08 · 0001213900-24-059612
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
2024-07-05 · 9999999995-24-002076
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
44,128,317 shares
Common Stock · Ticker CERO · Warrants to purchase shares of Common Stock at $10.00 and $1.39 per share · Selling stockholders only · Use of proceeds The company will not receive any proceeds from the resale of Common Stock by the Selling Securityholders
2024-06-27 · 0001213900-24-056757
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior 424B3 filing.
44,128,317 shares
Common Stock · Ticker CERO · Includes warrants exercisable at $10.00, $11.50, and other prices, with 5,000,000 shares issuable upon exercise of Preferred Warrants and 8,750,000 shares from Public Warrants · Selling stockholders only · Use of proceeds Selling stockholders will receive all proceeds from the resale
2024-06-05 · 0001213900-24-050103
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
44,523,704 shares
Common Stock · Exchange NASDAQ · Ticker CERO
2024-05-22 · 0001213900-24-045722
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows EFFECT in the pre-IPO sequence.
2024-05-06 · 0001213900-24-040148
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows S-1/A and confirms the priced prospectus.
Price $1.00 · 26,619,050 shares
Purchase Share · Exchange Nasdaq · Ticker CERO · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, with no proceeds to the company · Underwriters Keystone Capital Partners, LLC, Arena Business Solutions Global SPC II, Ltd
2024-05-01 · 0001213900-24-038547
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B5 and marks the registration effective.
2024-05-01 · 9999999995-24-001317
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
26,619,050 shares · Gross proceeds $0.00
Common Stock · Exchange Nasdaq · Selling stockholders only · Use of proceeds No issuer proceeds; all shares are sold by selling stockholders · Underwriters Keystone Capital Partners, LLC, Arena Business Solutions Global SPC II, Ltd
2024-04-26 · 0001213900-24-036671
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 425 in the pre-IPO sequence.
Price $1.00 · 26,619,050 shares
Purchase Share · Exchange Nasdaq · Ticker CERO · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders, no issuer proceeds · Underwriters Keystone Capital Partners, LLC, Arena Business Solutions Global SPC II, Ltd
2024-04-10 · 0001213900-24-031869
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2024-02-14 · 0001213900-24-013807
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B3 in the pre-IPO sequence.
2024-02-12 · 0001213900-24-012582
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B3 in the pre-IPO sequence.
2024-02-06 · 0001213900-24-010231
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 425 and confirms the priced prospectus.
2,000 shares · Gross proceeds $2,000,000
Series A Preferred Stock · Exchange NASDAQ · Warrants to purchase 125,000 shares of common stock with an exercise price based on the stock price · Use of proceeds To fund the Business Combination and related transactions
2024-02-06 · 0001213900-24-010236
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
10,493,945 shares
Class A · Exchange NASDAQ · Ticker CERO · Units consisting of one share of Class A Common Stock and one-half of one warrant · Warrants to purchase Class A Common Stock with exercise price adjustments based on conversion terms · Use of proceeds To facilitate the business combination with CERo Therapeutics, Inc. · Flags units, warrants
2024-01-22 · 0001213900-24-005374
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-4/A and marks the registration effective.
2024-01-19 · 9999999995-24-000155
S-4/A
amended
S-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior S-4/A filing.
Class A · Ticker PBAX · Warrants to purchase CERo preferred stock converted into warrants to acquire Class A Common Stock · Use of proceeds To facilitate the business combination with CERo Therapeutics, Inc.
2024-01-17 · 0001213900-24-003847
S-4/A
amended
S-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior 425 filing.
5,000,000 shares
Class A · Ticker PBAX · CERo warrants convert to Class A Common Stock with adjusted exercise prices · Use of proceeds To facilitate the business combination with CERo Therapeutics, Inc.
2024-01-09 · 0001213900-24-002005
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows S-4/A in the pre-IPO sequence.
2024-01-05 · 0001213900-24-001517
S-4/A
amended
S-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior 425 filing.
5,000,000 shares
Class A · Exchange NASDAQ · Ticker CERO · Warrants to purchase CERo preferred stock will convert into warrants to acquire Class A Common Stock · Use of proceeds To facilitate the business combination with CERo Therapeutics, Inc. · Flags dual_class
2023-12-18 · 0001213900-23-096240
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2023-12-11 · 0001213900-23-094786
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2023-09-08 · 0001213900-23-075420
S-4/A
amended
S-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior S-4/A filing.
5,000,000 shares
Class A · Ticker CERO · Converted to Class A Common Stock · Use of proceeds Merger and business combination
2023-08-14 · 0001213900-23-066368
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows S-4/A in the pre-IPO sequence.
2023-08-14 · 0001213900-23-066379
S-4/A
amended
S-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior 425 filing.
4,811,508 shares
Class A · Ticker CERO · CERo warrants converted to Class A Common Stock warrants · Use of proceeds Merger consideration and transaction expenses
2023-07-19 · 0001213900-23-058043
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2023-07-18 · 0001213900-23-057849
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2023-07-10 · 0001213900-23-055878
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows S-4 in the pre-IPO sequence.
2023-07-03 · 0001213900-23-053961
S-4
filed
S-4
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
4,811,508 shares
Class A Common Stock · Exchange Nasdaq · Ticker PBAX · Units consisting of one share of Class A Common Stock and one-half of one warrant · Warrants to purchase Class A Common Stock · Use of proceeds To facilitate the business combination with CERo Therapeutics, Inc. · Flags units
2023-06-07 · 0001213900-23-046942
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2023-06-05 · 0001193125-23-160389
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2022-12-07 · 0001193125-22-300148
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B4 in the pre-IPO sequence.
2022-10-31 · 0001193125-22-273359
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2022-10-31 · 0001193125-22-273887
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $10.00 · 15,500,000 shares · Gross proceeds $155,000,000
Class A · Exchange Nasdaq · Ticker PBAXU · Over-allotment 2,325,000 · One share of Class A common stock and one-half of one warrant · Each warrant entitles holder to purchase one share of Class A common stock at $11.50 per share, exercisable 30 days after initial business combination or 12 months from this offering, expiring five years after business combination · Use of proceeds Proceeds deposited into trust account for initial business combination · Flags dual_class, units, warrants · Underwriters Cantor Fitzgerald & Co.
2021-10-08 · 0001193125-21-294397
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1/A and registers the class of securities for exchange listing.
Cero Therapeutics Holdings, Inc. (formerly Phoenix Biotech Acquisition Corp.) filed Form 8-A to register its units, Class A common stock, and warrants for listing on NASDAQ. The filing incorporates by reference the previously filed registration statement (S-1/A) and outlines the structure of the securities, including unit components (share and warrant), pricing, and exchange listing details. The document emphasizes compliance with regulatory requirements for securities registration under Section 12(b) of the Exchange Act.
2021-10-05 · 0001193125-21-291626
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
Follows 8-A12B in the pre-IPO sequence.
The current filing for Cero Therapeutics Holdings, Inc. appears to be a CERT form, indicating a registration statement for securities. However, the provided text is non-readable, making it difficult to ascertain specific details about the company's offerings, financials, or structure. The previous filing (8-A12B) was for Phoenix Biotech Acquisition Corp., a separate entity, suggesting potential confusion or data mismatch.
2021-10-05 · 0001354457-21-001122
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows CERT and marks the registration effective.
2021-10-05 · 9999999995-21-003784
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $10.00 · 17,825,000 shares · Gross proceeds $178,250,000
Class A common stock · Exchange NASDAQ · Ticker CERO · Over-allotment 2,325,000 · Each unit consists of one share of Class A common stock and one-half of one warrant · Each unit includes one-half of one warrant · Flags units, warrants
Cero Therapeutics Holdings, Inc. (formerly Phoenix Biotech Acquisition Corp.) is a blank check company formed to effect a business combination. The filing details an IPO of 15.5 million units at $10.00 per unit, each consisting of one Class A share and a warrant. The company will use a trust account for redemptions, with sponsor participation in a private placement. The filing includes indemnification provisions, legal counsel details, and expense breakdowns for the offering.
2021-09-28 · 0001193125-21-285049
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Price $10.00 · 17,825,000 shares · Gross proceeds $178,250,000
Class A common stock · Exchange Nasdaq · Ticker PBAX · Over-allotment 2,325,000 · Units consisting of one share of Class A common stock and one-half of one warrant · Each warrant entitles the holder to purchase one share of Class A common stock at $11.50 per share · Use of proceeds For general corporate purposes and potential business combination · Flags units, warrants · Underwriters Cantor Fitzgerald & Co.
Phoenix Biotech Acquisition Corp. is a newly organized blank check company formed to effect a business combination with a biotechnology firm. The company is offering 15.5 million units at $10.00 per unit, each consisting of one share of Class A common stock and one-half of a warrant. The offering includes a 45-day option for underwriters to purchase additional units. Proceeds will be held in a trust account, with public stockholders entitled to redeem shares under certain conditions. The company is an emerging growth company with reduced reporting requirements.
2021-09-21 · 0001193125-21-278331
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
Price $10.00 · 15,500,000 shares · Gross proceeds $155,000,000
Class A · Exchange Nasdaq · Ticker PBAX · Over-allotment 2,325,000 · Units consist of one share of Class A common stock and one-half of one warrant · Each warrant entitles holder to purchase one share of Class A common stock at $11.50 per share · Use of proceeds To effect a business combination · Flags units, warrants · Underwriters Cantor Fitzgerald & Co.
Phoenix Biotech Acquisition Corp. is a blank check company formed to effect a business combination with a biotechnology firm. The current S-1 filing outlines an IPO of 15.5 million units at $10.00 per unit, each containing one Class A share and one-half of a warrant. The company plans to use a trust account for proceeds, with redemption rights for public shareholders. A private placement of additional units is also planned, with a 45-day underwriter option to cover over-allotments. The filing highlights risks related to the business combination, redemption terms, and lack of operating history.
2021-09-13 · 0001193125-21-271453
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Phoenix Biotech Acquisition Corp. is a blank check company formed to effect a merger or business combination, offering 15.5 million units at $10 each, consisting of Class A common stock and warrants. The filing outlines terms for a trust account, redemption rights for public stockholders, and a private placement by the sponsor. The company is an emerging growth company with reduced reporting requirements.
2021-07-08 · 0000950123-21-008524
Comparable Deals
8 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 8 using nearest neighbors.
Agomab Therapeutics NV
AGMB
same SICrecent IPO
Eikon Therapeutics, Inc.
EIKN
same SICrecent IPO
Aardvark Therapeutics, Inc.
AARD
same SIC grouprecent IPO
Veradermics, Inc
MANE
same SIC grouprecent IPO
MiniMed Group, Inc.
MMED
same sectorrecent IPO
SpyGlass Pharma, Inc.
SGP
same sectorrecent IPO
Lumexa Imaging Holdings, Inc.
LMRI
same sectorrecent IPO
Park Dental Partners, Inc.
PARK
same sectorrecent IPO
Recent News
No recent news stored for this issuer.